Clinical · Molecular biology
Molecular underpinnings of metastatic small renal masses
Summary
This study performed integrated morphological and molecular profiling, including whole-exome sequencing and RNA-Seq, on a multiinstitutional cohort of metastatic small renal masses (SRMs). The aim was to understand the molecular underpinnings of metastatic competence in these tumors, which are often managed with active surveillance. Researchers identified distinct genetic alterations in metastatic non-clear cell SRMs, such as NF2-altered tumors, ELOC-mutated RCC, and an mTOR-driven eosinophilic vacuolated tumor. Metastatic clear cell SRMs exhibited multi-hit aggressive genotypes, including recurrent losses of chromosomes 8p, 9, and 14q, along with co-occurring driver alterations in genes like BAP1 and mTOR pathway genes. Transcriptomic analyses revealed an enrichment of the NMF3 subtype, metabolic rewiring, and reduced cytotoxic immune effector function.
Critical appraisal
Clinical. This study has significant clinical implications by providing a biological framework for risk stratification in patients with small renal masses (SRMs) often considered for active surveillance. The identification of specific molecular signatures associated with metastatic competence in SRMs, including NF2, ELOC, mTOR, and BAP1 alterations, could justify early-phase studies to validate these predictive biomarkers. This could potentially change clinical practice by enabling earlier identification of patients at risk of metastasis, warranting more aggressive intervention rather than surveillance. Clinical impact could be seen in the medium term (3-5 years) if these markers are validated in larger cohorts.
Molecular biology. Researchers discovered molecular programs associated with metastatic competence in SRMs, including NF2 alterations, ELOC mutations, and mTOR-driven tumors in non-clear cell SRMs. For clear cell SRMs, aggressive multi-hit genotypes, including chromosomal losses (8p, 9, 14q) and co-occurring alterations in BAP1 and mTOR pathway genes, were identified. The technology used included whole-exome sequencing (WES) and RNA-Seq, allowing for in-depth genomic and transcriptomic analysis. Transcriptomic analyses also revealed an enrichment of the NMF3 subtype, metabolic rewiring, and reduced cytotoxic immune effector function. These discoveries have high analytical validity due to the integration of multiple "omics" techniques and could lead to the development of clinical tests based on liquid or tissue biopsies to identify these biomarkers and guide therapeutic decisions.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology